InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) Secures $14.5M in Underwritten Public Offering
April 7, 2021

InvestorNewsBreaks – Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) Secures $14.5M in Underwritten Public Offering

Cyclacel (NASDAQ: CYCC), a biopharmaceutical company developing innovative medicines based on cancer cell biology, has closed an underwritten public offering of 2,078,214 shares of its common stock, including 271,071 additional shares per the full exercise of the over-allotment option granted to the underwriters. Cyclacel secured approximately $14.5 million in gross proceeds, with each of the shares sold at the public offering price of $7.00. The company intends to use the proceeds from the offering to support its growth strategy, as well as for working capital and general corporate purposes, including research and development expenses and capital expenditures. Roth Capital Partners acted as co-manager for the offering.

To view the full press release, visit https://ibn.fm/8l41b

About Cyclacel Pharmaceuticals Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For more information about the company, visit www.Cyclacel.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up NetworkNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).